Icahn Down $60M on Healthcare Stocks This Week (AMLN, BIIB, CYBX, REGN, FOLD)

So far this week, in only two days of trading, activist investor Carl Icahn has lost about $60 million in value on his positions in several healthcare companies:

• Biogen (Nasdaq: BIIB) - down 1% this week; this is one of Icahn's top 3 holdings and with over 17 million shares, he has lost about $10.5 million in value.
  
• Amylin Pharmaceuticals (Nasdaq: AMLN) - down 17% this week; the FDA issued a notice on Monday warning that Amylin's Byetta drug could be linked to severe pancreatitis. The stock plummeted and with about 6.78 million shares, Icahn is down about $41 million since yesterday.
  
• Cyberonics (Nasdaq: CYBX) - down 6% this week; the FDA announcement related to Amylin has hurt many other pharmaceutical companies. Icahn currently holds about 2.51 million shares and has lost about $4 million on his investment in Cyberonics this week.
  
• Regeneron Pharmaceuticals (Nasdaq: REGN) - down 5.8% this week; Icahn owns about 2.5 million shares, meaning he has lost about $3.3 million in just two days.
  
• Amicus Therapeutics (Nasdaq: FOLD) - down 17% this week; after nearly hitting a 52-week high last week, shares of Amicus have fallen five days in a row as insiders have recently been selling. Although Icahn only holds about 200,000 shares, this week's sharp decline has taken about $570,000 in value from Icahn compared to his holdings at last Friday's close.

To see Icahn's entire portfolio, as well as real-time news related to the activist, check out StreetInsider.com's entity page on Mr. Icahn.

You May Also Be Interested In

• Price choppiness and volatility is here to stay - BMO
• B. Riley Financial (RILY) touching day low of $27, giving back half the day's gains
• IMAC Holdings (BACK) halted on volatility, up 38%